Oprymea (Pramipexole)
Dopamine agonist for the treatment of Parkinson's disease
Quick Facts About Oprymea
Key Takeaways About Oprymea
- Dopamine receptor stimulator: Oprymea works by activating dopamine D2/D3 receptors in the brain, helping control tremor, rigidity, and bradykinesia in Parkinson's disease
- Once-daily extended-release: The prolonged-release formulation only needs to be taken once per day, providing consistent symptom control
- Never stop suddenly: Abrupt discontinuation can cause neuroleptic malignant syndrome (NMS) – always taper gradually under medical supervision
- Watch for impulse control disorders: Report any unusual urges such as gambling, compulsive spending, binge eating, or hypersexuality to your doctor immediately
- Dose adjustment for kidney problems: Patients with reduced kidney function may need lower doses or less frequent dosing
What Is Oprymea and What Is It Used For?
Oprymea contains pramipexole, a non-ergot dopamine agonist that stimulates dopamine D2 and D3 receptors in the brain. It is approved for treating the symptoms of Parkinson's disease in adults, either alone or combined with levodopa, the most commonly used Parkinson's medication.
Parkinson's disease is a progressive neurological condition caused by the loss of dopamine-producing neurons in a brain region called the substantia nigra. Dopamine is a chemical messenger essential for coordinating smooth, controlled movement. When dopamine levels fall, patients experience characteristic motor symptoms: tremor at rest, muscle rigidity, slowness of movement (bradykinesia), and problems with balance and coordination.
Pramipexole belongs to a class of medications called dopamine agonists. Unlike levodopa, which the brain converts into dopamine, pramipexole directly stimulates dopamine receptors – specifically the D3 receptor subtype – mimicking the action of naturally produced dopamine. This mechanism helps restore more normal signaling in the brain circuits that control movement.
Oprymea is available in two formulations. Immediate-release tablets are taken two to three times daily, while extended-release (prolonged-release) tablets are designed to release the active ingredient slowly throughout the day and are taken just once daily. The extended-release formulation can simplify treatment regimens and may provide more stable plasma levels, reducing motor fluctuations experienced by some patients.
In early Parkinson's disease, Oprymea may be used as monotherapy, delaying the need for levodopa. In more advanced stages, it is commonly combined with levodopa, which may allow lower levodopa doses and reduce levodopa-related complications such as wearing-off phenomena and on-off fluctuations. Clinical trials have demonstrated that pramipexole significantly improves motor function scores on the Unified Parkinson's Disease Rating Scale (UPDRS) compared to placebo.
Pramipexole is marketed under several brand names worldwide, including Oprymea, Sifrol, Mirapex (United States), Derinik, Pramipexol Zentiva, Pramipexol STADA, Pramipexole Sandoz, and Pramipexol Teva Pharma. While the brand names differ, they all contain the same active ingredient and work in the same way.
What Should You Know Before Taking Oprymea?
Before starting Oprymea, your doctor needs to know about any kidney problems, heart disease, history of hallucinations or psychosis, and whether you or your family have noticed impulse control problems. Several conditions require special monitoring or dose adjustments.
Contraindications
Do not take Oprymea if you are allergic to pramipexole or any of the other ingredients in the tablets. The inactive ingredients include hypromellose, corn starch, colloidal anhydrous silica, and magnesium stearate. If you have experienced an allergic reaction to any pramipexole-containing medicine in the past, inform your doctor before starting treatment.
Warnings and Precautions
Several conditions and situations require special caution when using Oprymea. Discuss the following with your doctor before starting treatment:
- Kidney disease: Pramipexole is primarily excreted through the kidneys. Impaired renal function significantly affects drug clearance and may require dose reduction or extended dosing intervals to prevent accumulation and increased side effects.
- Hallucinations: Dopamine agonists can cause visual, auditory, or tactile hallucinations. These are more common in elderly patients and those taking higher doses. Most hallucinations are visual. If you experience hallucinations, contact your doctor promptly.
- Dyskinesia: If you have advanced Parkinson's disease and are also taking levodopa, you may develop abnormal involuntary movements (dyskinesia) during the dose titration period. Your doctor may need to adjust your levodopa dose.
- Dystonia: Some patients develop involuntary sustained muscle contractions, including forward bending of the head (antecollis), forward bending of the lower back (camptocormia), or sideways bending of the spine (pleurothotonus or Pisa syndrome). If this occurs, dose adjustment may be necessary.
- Excessive drowsiness and sudden sleep onset: Pramipexole can cause significant somnolence and episodes of suddenly falling asleep, sometimes without warning. This is particularly relevant for patients who drive or operate machinery.
- Psychosis: Symptoms comparable to schizophrenia may occur in susceptible individuals, particularly at higher doses.
- Vision changes: Regular eye examinations are recommended during treatment, as pramipexole may affect vision.
- Cardiovascular disease: Blood pressure should be monitored regularly, especially during initial treatment, as pramipexole can cause orthostatic hypotension (a drop in blood pressure when standing up).
Dopamine agonists including pramipexole can cause impulse control disorders. These are strong urges to behave in ways that may harm you or others. They can include:
- Pathological gambling despite serious personal or financial consequences
- Altered or increased sexual interest and behavior (hypersexuality)
- Uncontrollable excessive shopping or spending
- Binge eating or compulsive eating beyond what is needed
Tell your doctor immediately if you or your family/caregivers notice any of these behaviors. Your doctor may need to adjust or stop the medication.
Patients or caregivers should also watch for signs of mania (feeling agitated, elated, or overexcited) or delirium (reduced awareness, confusion, loss of contact with reality). These psychiatric effects may require dose reduction or discontinuation.
After stopping or reducing the dose of Oprymea, a withdrawal syndrome known as dopamine agonist withdrawal syndrome (DAWS) may occur. Symptoms include depression, apathy, anxiety, fatigue, sweating, and pain. If these symptoms persist for more than a few weeks, your doctor may need to adjust your treatment plan.
Oprymea extended-release tablets are specially designed to release the active ingredient gradually after swallowing. Parts of the tablet shell may sometimes appear in the stool and resemble whole tablets. This is normal and does not mean the medication has not been absorbed. Do not be alarmed if you notice this.
Pregnancy and Breastfeeding
The effects of pramipexole on unborn babies have not been adequately studied in humans. Animal studies are insufficient to fully rule out potential harm. Therefore, Oprymea should not be taken during pregnancy unless clearly necessary and specifically advised by your doctor. If you are pregnant, think you may be pregnant, or are planning to become pregnant, discuss the risks and benefits with your healthcare provider before using this medicine.
Oprymea should not be used during breastfeeding. Pramipexole may reduce breast milk production through its dopamine-agonist properties (dopamine inhibits prolactin, the hormone that stimulates milk production). It may also pass into breast milk and reach the nursing infant. If treatment with Oprymea is medically necessary, breastfeeding should be discontinued.
Driving and Operating Machinery
Oprymea can cause hallucinations, excessive drowsiness, and sudden episodes of falling asleep – sometimes without any prior warning signs of sleepiness. If you experience any of these effects, you must not drive a car, ride a bicycle, or operate tools or machinery. Report these effects to your doctor immediately. The risk of drowsiness is increased when Oprymea is taken with other sedating medications or alcohol.
How Does Oprymea Interact with Other Drugs?
Oprymea can interact with several medications. The most important interaction is with antipsychotic drugs, which should be avoided. Other drugs that share the same kidney excretion pathway as pramipexole may increase blood levels and side effects.
Pramipexole is primarily eliminated unchanged through the kidneys via active tubular secretion. Drugs that are also secreted by the renal cation transport system or that inhibit this system can reduce pramipexole clearance, leading to higher blood levels and an increased risk of side effects. Always tell your doctor about all medications you are taking, including over-the-counter medicines, herbal remedies, and supplements.
Major Interactions
Antipsychotic medications should be avoided while taking Oprymea. Antipsychotics work by blocking dopamine receptors – the exact opposite mechanism to pramipexole. Taking them together can reduce the effectiveness of both medications and worsen Parkinson's symptoms. If antipsychotic treatment is necessary, your neurologist and psychiatrist should collaborate closely on an appropriate treatment strategy.
Levodopa: When starting Oprymea in patients already taking levodopa, the levodopa dose may need to be reduced. The combination can increase the risk of dyskinesia. Your doctor will carefully titrate both medications to find the optimal balance.
Other Drug Interactions
The following medications may interact with pramipexole by competing for the same renal excretion pathway, potentially increasing pramipexole blood levels:
| Interacting Drug | Used For | Interaction Type | Clinical Significance |
|---|---|---|---|
| Cimetidine | Excess stomach acid and ulcers | Reduces renal clearance of pramipexole | Moderate – monitor for increased side effects |
| Amantadine | Parkinson's disease | Competes for renal tubular secretion | Moderate – dose adjustment may be needed |
| Mexiletine | Irregular heartbeat (ventricular arrhythmia) | Competes for renal cation transport | Moderate – monitor pramipexole levels |
| Zidovudine | HIV infection | Competes for renal tubular secretion | Moderate – monitor for increased effects |
| Cisplatin | Various cancers | May affect renal elimination | Moderate – renal function monitoring essential |
| Quinine | Night leg cramps, falciparum malaria | Competes for renal cation transport | Moderate – use with caution |
| Procainamide | Irregular heartbeat | Competes for renal tubular secretion | Moderate – use with caution |
Use caution with alcohol and any medications that cause drowsiness (such as benzodiazepines, antihistamines, or opioids) while taking Oprymea. The combination can significantly increase drowsiness and impair your ability to drive or operate machinery safely.
Oprymea can be taken with or without food. Food does not significantly affect the absorption of pramipexole, though taking it with food may reduce nausea in some patients.
What Is the Correct Dosage of Oprymea?
For extended-release tablets, the starting dose is 0.26 mg once daily, gradually increased every 5–7 days to a typical maintenance dose of 1.05 mg/day. The maximum dose is 3.15 mg/day. Extended-release tablets must be swallowed whole – never crushed, chewed, or split.
Always take Oprymea exactly as prescribed by your doctor. The dose is carefully titrated (gradually increased) over several weeks to find the lowest effective dose that adequately controls your symptoms while minimizing side effects. The titration schedule for extended-release tablets is shown below.
Adults – Parkinson's Disease (Extended-Release Tablets)
| Week | Daily Dose | Tablets |
|---|---|---|
| Week 1 | 0.26 mg | One 0.26 mg extended-release tablet |
| Week 2 | 0.52 mg | One 0.52 mg tablet OR two 0.26 mg tablets |
| Week 3 | 1.05 mg | One 1.05 mg tablet OR two 0.52 mg tablets |
The standard maintenance dose is 1.05 mg once daily. However, your doctor may increase the dose further if needed, up to a maximum of 3.15 mg per day. A lower maintenance dose of 0.26 mg daily is also possible if it provides adequate symptom control.
Take the extended-release tablet at approximately the same time each day. Swallow the tablet whole with water. Do not chew, crush, or split the extended-release tablet, as this destroys the slow-release mechanism and may cause the entire dose to be released at once, leading to an overdose and increased side effects.
Switching from Immediate-Release to Extended-Release
If you are switching from Oprymea immediate-release tablets to extended-release tablets, your doctor will base the new dose on the total daily dose you were already taking. Take your last immediate-release tablet dose as usual in the evening, then start the extended-release tablet the next morning. Do not take any more immediate-release tablets after starting the extended-release formulation.
Patients with Kidney Disease
If you have kidney disease, your doctor may prescribe a modified dosing regimen. For moderate kidney impairment, the starting dose is typically 0.26 mg every other day during the first week. The dosing frequency may then be increased to once daily, with subsequent dose increases made in 0.26 mg increments.
For patients with severe kidney disease, your doctor may need to switch you to a different pramipexole formulation or consider alternative treatments. If your kidney function deteriorates during treatment, contact your doctor as soon as possible for dose reassessment.
Children and Adolescents
Oprymea is not recommended for children and adolescents under 18 years of age. Parkinson's disease is extremely rare in this age group, and the safety and efficacy of pramipexole have not been established in pediatric populations.
Missed Dose
If you forget to take a dose of the extended-release tablet but remember within 12 hours, take your tablet immediately and then take the next dose at the usual time. If more than 12 hours have passed since the missed dose, skip it and take your next dose at the regular scheduled time. Do not take a double dose to make up for a forgotten dose.
Overdose
If you accidentally take too many tablets, contact your doctor or go to the nearest emergency department immediately. Symptoms of overdose may include nausea, vomiting, restlessness (inability to sit still), and any of the side effects described in the side effects section at higher intensity. There is no specific antidote for pramipexole overdose; treatment is supportive and symptom-based.
Do not stop taking Oprymea without first consulting your doctor. If treatment needs to be discontinued, your doctor will reduce the dose gradually over a period of days to weeks. Abrupt discontinuation of pramipexole can cause neuroleptic malignant syndrome (NMS), a potentially life-threatening condition with symptoms including:
- Akinesia (loss of muscle movement)
- Severe muscle rigidity
- Fever
- Unstable blood pressure
- Tachycardia (rapid heart rate)
- Confusion and reduced level of consciousness (coma)
Additionally, dopamine agonist withdrawal syndrome (DAWS) may occur, causing depression, apathy, anxiety, fatigue, sweating, and pain. Contact your doctor if you experience these symptoms after dose reduction.
What Are the Side Effects of Oprymea?
Like all medicines, Oprymea can cause side effects, although not everyone experiences them. The most common side effects are dyskinesia (abnormal involuntary movements), drowsiness, dizziness, and nausea. Serious side effects include hallucinations, impulse control disorders, and sudden sleep episodes.
Side effects are classified below by their frequency of occurrence based on clinical trial data from 2,762 patients treated with pramipexole. Understanding the frequency helps you and your doctor weigh the benefits of treatment against potential risks and recognize side effects early.
Very Common
May affect more than 1 in 10 people
- Dyskinesia (abnormal, involuntary movements of limbs or face)
- Somnolence (excessive drowsiness)
- Dizziness
- Nausea
Common
May affect up to 1 in 10 people
- Urge to behave in unusual ways (impulse control disorders)
- Hallucinations (seeing, hearing, or feeling things that are not there)
- Confusion
- Fatigue (tiredness)
- Insomnia (difficulty sleeping)
- Peripheral edema (fluid retention, typically in the legs)
- Headache
- Hypotension (low blood pressure)
- Abnormal dreams
- Constipation
- Visual impairment
- Vomiting
- Weight loss and decreased appetite
Uncommon
May affect up to 1 in 100 people
- Paranoia (e.g., excessive health anxiety)
- Delusion (distorted perception of reality)
- Excessive daytime sleepiness and sudden sleep onset
- Amnesia (memory loss)
- Hyperkinesia (restlessness, inability to remain still)
- Weight gain
- Allergic reactions (rash, itching, hypersensitivity)
- Syncope (fainting)
- Heart failure (causing breathlessness and swollen ankles)
- Inappropriate ADH secretion
- Restlessness
- Dyspnea (breathing difficulty)
- Hiccups
- Pneumonia (lung infection)
- Impulse control disorders: pathological gambling, hypersexuality, compulsive shopping, binge eating
- Delirium (reduced awareness, confusion, loss of reality)
Rare
May affect up to 1 in 1,000 people
- Mania (feeling agitated, elated, or overexcited)
After stopping or reducing the dose of Oprymea, some patients experience a withdrawal syndrome with symptoms including depression, apathy, anxiety, fatigue, sweating, or pain. The frequency of this syndrome is not precisely known from clinical trial data. If you experience these symptoms after a dose change, contact your doctor.
Tell your doctor about any side effects you experience. Early reporting of side effects allows your doctor to adjust your treatment to minimize discomfort while maintaining adequate symptom control. For any side effect that is severe, persistent, or causes you concern, seek medical advice promptly.
How Should You Store Oprymea?
Store Oprymea in its original packaging to protect from moisture. Keep it out of the sight and reach of children. No special temperature storage conditions are required. Do not use after the expiry date printed on the packaging.
Proper storage of medications is essential to maintain their effectiveness and safety. Follow these guidelines for Oprymea:
- Keep out of reach of children: Store all medications in a secure location where children cannot access them.
- Original packaging: Keep the tablets in the original blister pack to protect them from moisture.
- No special temperature requirements: Store at normal room temperature. Avoid extreme heat or direct sunlight.
- Check expiry date: Do not use the medicine after the expiry date (EXP) printed on the carton and blister. The expiry date refers to the last day of that month.
- Disposal: Do not dispose of medications via wastewater or household waste. Return unused medicines to your pharmacy for safe disposal to protect the environment.
What Does Oprymea Contain?
Each Oprymea extended-release tablet contains pramipexole (as dihydrochloride monohydrate) as the active ingredient, along with hypromellose, corn starch, colloidal anhydrous silica, and magnesium stearate as inactive ingredients.
The active substance is pramipexole. Extended-release tablets are available in the following strengths (expressed as pramipexole base, with the equivalent pramipexole dihydrochloride monohydrate salt amount in parentheses):
| Pramipexole Base | Salt Equivalent | Tablet Marking | Appearance |
|---|---|---|---|
| 0.26 mg | 0.375 mg | P1 | White, round, biconvex, 10 mm |
| 0.52 mg | 0.75 mg | P2 | White, round, biconvex, 10 mm |
| 1.05 mg | 1.5 mg | P3 | White, round, biconvex, 10 mm |
| 1.57 mg | 2.25 mg | P12 | White, round, biconvex, 10 mm |
| 2.1 mg | 3 mg | P4 | White, round, biconvex, 10 mm |
| 2.62 mg | 3.75 mg | P13 / 262 | White, round, biconvex, 10 mm |
| 3.15 mg | 4.5 mg | P5 / 315 | White, round, biconvex, 10 mm |
The inactive ingredients (excipients) are: hypromellose (a polymer that creates the extended-release matrix), corn starch, colloidal anhydrous silica (a flow agent), and magnesium stearate (a lubricant). These are common pharmaceutical excipients with well-established safety profiles.
Oprymea extended-release tablets are supplied in blister packs containing 10, 30, 90, or 100 tablets. Not all pack sizes may be available in every country.
Frequently Asked Questions About Oprymea
Oprymea (pramipexole) is a dopamine agonist used to treat the symptoms of Parkinson's disease in adults. It can be used alone (monotherapy) or in combination with levodopa. Pramipexole works by stimulating dopamine receptors in the brain to help control movement, reduce tremor, stiffness, and slowness of movement. It is available as both immediate-release and extended-release tablets.
The most common side effects (affecting more than 1 in 10 patients) include dyskinesia (abnormal involuntary movements), somnolence (drowsiness), dizziness, and nausea. Common side effects (up to 1 in 10) include hallucinations, confusion, insomnia, fatigue, peripheral edema, headache, low blood pressure, constipation, abnormal dreams, and vomiting. Most side effects are dose-dependent and may improve over time or with dose adjustment.
No. You should never stop taking Oprymea suddenly without medical supervision. Abrupt discontinuation can cause neuroleptic malignant syndrome (NMS), a potentially life-threatening condition with symptoms including severe muscle rigidity, fever, unstable blood pressure, rapid heart rate, and altered consciousness. Your doctor will gradually reduce the dose over days to weeks when stopping treatment. A withdrawal syndrome with depression, apathy, and anxiety may also occur.
Yes, Oprymea and other dopamine agonists can cause impulse control disorders in some patients. These may include pathological gambling, increased sexual drive (hypersexuality), compulsive shopping or spending, and binge eating. These behaviors can have serious personal and financial consequences. If you or your family notice any unusual behavioral changes, contact your doctor immediately, as dose adjustment or discontinuation may be necessary.
Oprymea immediate-release tablets are taken two to three times daily, while extended-release (prolonged-release) tablets are taken just once per day. The extended-release formulation releases pramipexole gradually throughout the day, providing more consistent blood levels. When switching from immediate-release to extended-release, the total daily dose usually remains the same. Take your last immediate-release dose in the evening and start the extended-release tablet the next morning.
The effects of Oprymea on unborn babies are not well established. Oprymea should generally not be used during pregnancy unless clearly necessary and specifically advised by your doctor. It should also not be used during breastfeeding, as it may reduce breast milk production and pass into breast milk. If you are pregnant, planning pregnancy, or breastfeeding, discuss your treatment options with your healthcare provider.
References
This article is based on the following peer-reviewed sources and authoritative medical guidelines:
- European Medicines Agency (EMA). Oprymea – Summary of Product Characteristics. Last updated 2024. European public assessment report (EPAR).
- Movement Disorder Society. Evidence-Based Medicine Review: Update on Treatments for the Motor Symptoms of Parkinson's Disease. Movement Disorders. 2018;33(8):1248-1266.
- NICE Clinical Guideline NG71. Parkinson's Disease in Adults. National Institute for Health and Care Excellence. Updated 2024.
- Schapira AHV, et al. Pramipexole in patients with early Parkinson's disease (PROUD): a randomised delayed-start trial. Lancet Neurology. 2013;12(8):747-755.
- Weintraub D, et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3,090 patients. Archives of Neurology. 2010;67(5):589-595.
- World Health Organization (WHO). Model List of Essential Medicines – 23rd List. Geneva: WHO; 2023.
- Antonini A, et al. Switching from immediate- to extended-release pramipexole in early Parkinson's disease. Movement Disorders. 2010;25(14):2362-2369.
- Connolly BS, Lang AE. Pharmacological treatment of Parkinson disease: a review. JAMA. 2014;311(16):1670-1683.
About Our Medical Editorial Team
This article was written and reviewed by the iMedic Medical Editorial Team, comprising board-certified physicians and clinical pharmacologists with expertise in neurology and movement disorders. Our editorial process follows the GRADE evidence framework, and all medical claims are verified against current international guidelines.
iMedic Medical Editorial Team – Specialists in neurology and clinical pharmacology with peer-reviewed research experience.
iMedic Medical Review Board – Independent panel ensuring accuracy according to EMA, FDA, and NICE guidelines.
Evidence Standard: All information in this article meets Evidence Level 1A, based on systematic reviews, randomized controlled trials, and authoritative clinical guidelines (EMA SmPC, NICE NG71, Movement Disorder Society Reviews). No commercial funding or pharmaceutical sponsorship.